Background. Novel therapeutic approaches are needed to attack persistent proviral human immunodeficiency type 1 (HIV-1) infection. Hexamethylbisacetamide (HMBA), a hybrid bipolar compound, induces expression of the HIV-1 promoter in the long terminal repeat (LTR) region in a Tat-independent manner but mimics the effect of Tat, overcoming barriers to LTR expression and increasing the processivity of LTR transcription complexes.
T cells poses a major obstacle to the eradication of human immunodeficiency virus type 1 (HIV-1) infection [1, 2] . In combination with foreseeable improvements in antiretroviral therapy (ART), approaches that target latently infected cells could lead to the clearance of established HIV-1 infection. Previous strategies to induce expression and clearance of quiescent infection via the administration of intensified ART in conjunction with the administration of immune activators has so far yielded discouraging results [3] [4] [5] . New approaches to clear latently infected cells include histone deacetylase (HDAC) inhibitors, interleukin-7 (IL-7), and hexamethylbisacetamide (HBMA) [6 -11] .
Mechanisms that maintain HIV-1 latency may be inhibited as a selective therapeutic strategy to target latently infected cells. However, the mechanisms of proviral inactivity are likely multifactorial [12] . Chromatin modifications contribute to proviral quiescence, as the recruitment of the chromatin-remodeling enzyme HDAC to the HIV-1 promoter in the long terminal repeat (LTR) region leads to proviral repression [13] [14] [15] . Nuclear factor B (NF-B) subunit p50 [16] and Sp1/cMyc [17] have also recently been shown to recruit HDAC to the LTR region. Small molecules that specifically inhibit recruitment of HDAC by late simian virus 40 transcription factor to the HIV-1 promoter and molecules that are nonselective inhibitors of HDAC both induce transcription and expression of HIV-1 in latently infected cells [7, 10, 15] . However, because initiation of HIV-1 transcription can occur during latency, abortive transcriptional elongation also contributes to proviral quiescence [18] .
The HIV-1 core promoter contains 3 binding sites for the general transcription factor Sp1, and results of genomic footprinting experiments suggest these sites are accessible for the initiation of transcription [19] . However, in the absence of the HIV-1 transactivator Tat, transcription is nonprocessive. A positioned nucleosome, Nuc 1, lies immediately downstream of the transcription start site, regardless of the site of proviral integration, and is displaced during transcriptional activation [20, 21] . Nuc 1 may play a central role in the suppression of HIV-1 transcription during latency when Tat is limiting [20 -22] . HMBA, a hybrid bipolar compound, remodels the HIV-1 promoter and induces HIV-1 expression in latently infected cell lines in the absence of Tat [11] . Clinical trials of HMBA in patients with cancer suggests that it may be a prototype molecule for the creation of therapeutics to purge the proviral reservoir. Here, we will show that HMBA induces HIV-1 expression in latently infected resting memory CD4 ϩ T cells obtained from aviremic patients treated with ART by inducing phosphorylation of the C-terminal domain of RNA polymerase II (RNA Pol II) in a Tat-independent but cyclin-dependent kinase 9 (CDK9)-dependent manner. HMBA increases the nuclear level of CDK9, allowing its recruitment by Sp1 to the HIV-1 promoter. Phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC-) signaling play key roles in induction of HIV-1 expression.
SUBJECTS, MATERIALS, AND METHODS

Limiting dilution culture of latently infected CD4
؉ T cells from HIV-1-positive donors. Lymphocytes were obtained by continuous-flow leukophoresis from stable, HIV-1-infected volunteers receiving ART. All volunteers had a plasma HIV-1 RNA load of Ͻ50 copies/mL for Ͼ6 months and a CD4 ϩ cell count of Ͼ300 cells/L. Human subjects committee-approved informed consent was obtained from all patients. Isolation of CD4 ϩ T cells and recovery and quantification of replicationcompetent HIV-1 were performed as described in detail elsewhere [2, 6, 9] . Cell culture, antibody, and reagents. Jurkat J89GFP T cell and HeLa-CD4-LTR-CAT lines were cultured as described elsewhere [11, 23] . HMBA and 5,6-dichloro-1-␤-Dribofuranosylbenzimidazole riboside (DRB) were obtained from Sigma. Gö6976, Gö6983, a PKC-␤1 inhibitor (3-(1-(3-imidazol-1-ylpropyl)-1H-indol-3-yl)-4-anilino-1H-pyrrole-2,5-dione), and LY294002 were obtained from Calbiochem. Polyclonal antibodies against human CDK9 (H-169), cyclin T1 (CycT1; H-245), RNA Pol II (N-20), and lamin B1 (H-90) were obtained from Santa Cruz Biotechnology. Anti-Sp1 (ab13370) and anti-hexamethylenebisacetamide-induced protein 1 (HEXIM1; ab28016) polyclonal antibodies were obtained from Abcam. Monoclonal antibodies (mAb) against phosphoserine 2 (H5) and against phosphoserine 5 (H14) were obtained from Covance.
Flow cytometry. HIV-1 expression induced by HMBA in J89GFP cells was evaluated by measurement of green fluorescent protein (GFP) expression with a flow cytometer. Briefly, 48 h after exposure to HMBA, cells were washed twice, fixed in 200 L of PBS with 2% formaldehyde, incubated overnight at 4°C in the dark, and analyzed by flow cytometry, using a FACScan flow cytometer and Cellquest software (BD). Cell populations analyzed were defined on the basis of their low-angle and 90°light scattering properties. Untreated cells were used to set markers that defined positive reactivity.
Immunoprecipitation and Western blot assays. Nuclear fractions were used for immunoprecipitation and Western blot assays as described elsewhere [23] . For Western blot analysis, the pellet was resuspended in 100 L of RIPA buffer that contained phosphatase inhibitors (1 mmol/L of NaF and 1 mmol/L of Na 3 VO 4 ) and 5 L of a protease inhibitor cocktail, incubated on ice for 5 min, and centrifuged at 20,000 g for 10 min at 4°C to pellet the cellular debris. For immunoprecipitation, the pellet was resuspended in 125 L of CelLytic reagent (Sigma) that contained a protease inhibitor cocktail and was incubated on ice for 20 min with frequent gentle mixing. Lysates were spun at 20,000 g for 10 min at 4°C to pellet cellular debris, and supernatants were incubated with the appropriate antibody overnight at 4°C, followed by 2-h incubation with 40 L of protein G plus/protein A agarose beads. Immune complexes were washed 3 times in 1 mL of lysis buffer (50 mmol/L of Tris HCl [pH 7.5], 150 mmol/L of NaCl, 0.1% of NP40, 1 mmol/L of NaF, and 1 mmol/L of Na 3 VO 4 ). Antibody-bound proteins were dissolved by boiling in 2ϫ NuPAGE sample buffer for 5 min at 95°C (Invitrogen), after which they were subjected to Western blotting.
Chromatin immunoprecipitation (ChIP) assay. A ChIP assay (Millipore) was performed in accordance with the manufacturer's protocol. Immunoprecipitated DNA was quantitated by polymerase chain reaction (PCR), using a primer set specific for the U3 region of HIV-1 LTR (forward primer: 5'-TGGAGGTTTGACAGCCGCCTA; reverse primer: 5'-AGGCTTAAGCAGTGGGTTCCCTA). Semiquantitative PCR was performed using Gotaq Green Master Mix (Promega) for 30 -32 cycles; 2-5 L of precipitated DNA was analyzed in a 25-L PCR reaction. PCR products were resolved on 1.5% agarose gel and visualized by ethidium bromide staining.
RNA interference analysis. Mammalian Sp1 siRNA expression plasmid pKD-Sp1-v1, negative control siRNA expression plasmid pKD-NegCon-v1, and vector pKD were obtained from Millipore. A total of 1.5 ϫ 10 6 HeLa-CD4-LTR-CAT cells were seeded overnight in a 60-mm tissue culture plate without antibiotics, and transfection of siRNA was performed using Lipofectamine 2000 reagents (Invitrogen) in accordance with the manufacturer's protocol.
RESULTS
HMBA induces outgrowth of HIV-1 from resting CD4 ؉ T cells.
We measured the ability of HMBA to induce expression of quiescent replication-competent proviral genomes in resting CD4 ϩ T cells obtained as described elsewhere from aviremic HIV-1-infected donors [9, 10] . Treatment of cells with 2.5 mmol/L of HMBA induced viral outgrowth in resting cells harvested from 3 patients and tested under standard assay conditions. However, outgrowth in these conditions was not as frequent as that following global mitogen activation with phytohemagglutinin (PHA), IL-2, and irradiated allogeneic cells (table 1) .
Because prolonged exposure to HMBA induces apoptosis (unpublished observations) as well as down-regulation of CD4 ϩ T cell expression [11] , we subsequently pulsed cultures with HMBA for 6 -24 h before coculture. Notably, HMBA induced HIV-1 outgrowth with much higher frequency in resting cells under these conditions. Because of the low frequency of latently infected cells, our studies do not have the statistical power to robustly compare the efficiency of induction of HIV-1 expression by HMBA with that by PHA. However, these findings clearly demonstrate that HMBA has the potential to induce viral expression from latently infected resting CD4 ϩ T cells.
HMBA induces hyperphosphorylation of the C-terminal domain of RNA Pol II. Because the viral transactivator Tat overcomes multiple obstacles to HIV-1 expression, HIV-1 latency has been described as a state of Tat deficiency [11, 24] . Similar to Tat, HMBA increases elongation during HIV-1 transcription [11] . Tat interacts with and recruits positive transcription elongation factor b (P-TEFb), composed of CycT1 and CDK9, to the HIV-1 promoter, resulting in hyperphosphorylation of the C-terminal domain of RNA Pol II and increased transcriptional processivity [25, 26] . We investigated whether HMBA recapitulates this aspect of Tat function. We treated HeLa-CD4-LTR-CAT cells, which carry 1 copy of the LTR-reporter gene construct but are devoid of Tat, with 5 mmol/L of HMBA. This concentration exhibits maximal expression without an appreciable effect on cell viability, as shown in our previous study [11] . Nuclear extracts were prepared serially after treatment, and RNA Pol II phosphorylation at serine 2 (Ser2) and serine 5 (Ser5) was measured by use of phospho-specific antibodies. We observed that HMBA induced hyperphosphorylation of both Ser2 and Ser5 of the RNA Pol II C-terminal domain, which peaked 6 -9 h after HMBA treatment (figure 1). HMBA treatment of J89GFP Jurkat T cell lines, which carry a single copy of an entire HIV-1 genome that encodes GFP and a functional Tat transactivator, yielded similar results (data not shown). Because HMBA increases polymerase processivity [11] , these results show that activation of the HIV-1 promoter by HMBA correlates with phosphorylation of the C-terminal domain of RNA Pol II in the presence or absence of Tat.
Hyperphosphorylation of the C-terminal domain of RNA Pol II and activation of HIV-1 expression by HMBA are dependent on CDK9. Although Ser2 C-terminal domain phosphorylation is typically mediated by CDK9, HMBA is also known to induce PKC signaling [27] . To clarify the mechanism through which HMBA phosphorylates the C-terminal domain, we treated HeLa-CD4-LTR-CAT cells with DRB and flavopiridol (provided by the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health [Bethesda, MD]), 2 ATP analogs that specifically inhibit the kinase activity of CDK9, before treatment with HMBA. Treatment of cells with DRB or flavopiridol resulted in abrogation of HMBA-mediated Ser5 and Ser2 phosphorylation of the Pol II C-terminal domain ( figure  2A ). Next, we treated J89GFP with several concentrations of flavopiridol ( figure 2B ). At a concentration of 30 nmol/L, we observed 50% inhibition of HIV-1 expression in response to HMBA treatment, consistent with the IC 50 for HIV-1 transcription [28] . At 120 nmol/L, flavopiridol abrogated HMBAinduced HIV-1 expression. These concentrations are insufficient to block cellular transcription [29] . These results led us to conclude that HMBA induces HIV-1 expression in a P-TEFbdependent manner. HMBA modulates the nuclear level of CDK9. HIV-1 transcription is very sensitive to CDK9 activity. Diverse signals that upregulate CycT1 and CDK9 production increase HIV-1 transcription and can upregulate HIV-1 replication in latently infected resting CD4 ϩ T cells [24, 28, 30 -32] . We measured CycT1 and CDK9 levels in nuclear extracts of HeLa-CD4-LTR-CAT cells before and after HMBA exposure. We observed robust expression of CycT1 at baseline, without a significant change following HMBA treatment (figure 3). However, after HBMA treatment, it was surprising to find that levels of CDK9 increased in a time-dependent fashion and were correlated with HMBAinduced Ser2 and Ser5 hyperphosphorylation. HEXIM1 expression, which is known to increase in response to HMBA, also increased in a time-dependent manner [33] . HEXIM1 is an inhibitory protein that sequesters P-TEFb into an inactive complex and negatively regulates its activity [34, 35] . These results suggested that, because of increasing HEXIM1 sequestration, CDK9 might be unable to act on polymerase at the LTR. How then is P-TEFb recruited to the HIV-1 promoter to increase transcriptional elongation?
Sp1 binds to and recruits CycT1/CDK9 to the HIV-1 promoter. CDK9 activity is required for transcription of several genes, but it must be recruited to target promoters (reviewed by Peterlin and Price [36] ). How HMBA causes P-TEFb recruitment and activity at the HIV-1 LTR in the absence of Tat is not clear. Upon binding to acetylated histones H3 and H4, Brd4 can Tat-independent manner. HeLa-CD4-LTR-CAT cells were treated with 5 mmol/L of HMBA; nuclear extract was made at indicated time points and subjected to Western blot analysis. Phosphorylation-specific monoclonal antibodies showed an increase in the nuclear level of RNA Pol II phosphorylated at serine 2 (Ser2) and serine 5 (Ser5). Antibodies that recognized both the phosphorylated (II o ) and unphosphorylated form (II a ) of RNA Pol II showed increasing C-terminal domain phosphorylation after HMBA exposure. Anti-lamin B1 antibody was used as a loading control for nuclear protein. Results are representative of 3 independent experiments.
recruit P-TEFb to promoters [37] . However, HMBA does not induce histone hyperacetylation, despite its structural similarity to HDAC inhibitors [11, 38] . Therefore, we hypothesized that a modest increase in the nuclear level of P-TEFb might allow its recruitment to the LTR by a cellular factor. Yedavalli et al. [39] suggested that Sp1 can recruit P-TEFb to the HIV-1 promoter in a Tat-independent manner. Although NF-B can recruit P-TEFb to the IL-8 promoter [40] , HMBA can activate HIV-1 expression in the absence of NF-B binding sites but requires Sp1 binding sites [41] . Similar findings were reported by Antoni et al. [42] in a chronically infected Jurkat T cell line, J⌬K, containing a deletion of the NF-B binding site in the LTR.
We therefore hypothesized that HMBA mediated an increase in the nuclear level of CDK9 and that its recruitment to the HIV-1 LTR region occurred via an interaction with Sp1. Nuclear extract were prepared after HMBA treatment, and coimmunoprecipitation studies were performed. Anti-Sp1 antibody coprecipitated increasing amounts of endogenous CycT1 after HMBA exposure; this complex was free of the inhibitory protein HEXIM1 ( figure 4A ). This finding suggested that CycT1/CDK9 bound to Sp1 was not sequestered in an inactive HEXIM1-7SK snRNA-P-TEFb ternary complex. Reciprocally, anti-CycT1 and anti-CDK9 antibodies coprecipitated endogenous Sp1, whereas control IgG did not ( figure 4B) . However, the response to HMBA is complex: there is a decrease in CycT1/CDK9 associated with Sp1 for 6 h after HMBA treatment, followed by a robust increase. We also observed an increased recovery of HEXIM1 with anti-CycT1 and anti-CDK9 after 6 h. It was unclear if Sp1-associated and HEXIM1-associated CycT1/CDK9 represented discrete complexes or co-occupied a large protein complex.
To demonstrate that CycT1/CDK9 occupancy at the LTR required the presence of Sp1, ChIP analysis was performed. HMBA treatment induced a significant increase in the occupancy of CDK9 at the HIV-1 promoter, in parallel with an increase in Sp1-associated CycT1/CDK9 (figure 4C). We measured RNA interference to determine the specificity of CDK9 recruitment. After knockdown of Sp1 by siRNA, occupancy of CDK9 at the LTR was drastically reduced, as revealed by the ChIP assay ( figure 4D ). In contrast, occupancy of CDK9 at the LTR in cells treated with scrambled control siRNAs was similar to that in untreated cells. We also measured the effect of HMBA on the occupancy of CDK9 at the HIV-1 promoter in siRNAtreated cells. We observed an increase in the occupancy of CDK9 at the LTR in control siRNA-HMBA-treated cells and vector-HMBA-treated cells, compared with CDK9 occupancy in Sp1 siRNA-HMBA-treated cells, confirming that Sp1 mediated recruitment of P-TEFb to the HIV-1 promoter despite increases in the level of HEXIM1 ( figure 4E) .
PKC-and PI3K modulate HMBA-induced HIV-1 expression. Because phosphorylation of CDK9 plays a key role in its nuclear localization and activity, we hypothesized that HMBA must induce a specific kinase to mediate CDK9 recruitment to the LTR [43, 44] . We incubated J89GFP cells with HMBA in the presence of specific inhibitors of kinases implicated in HIV-1 activation. Treatment of a J89-GFP cell line with the PI3K inhibitor LY294002 resulted in dose-dependent decreased expression of HIV-1 in response to HMBA (figure 5A). A concomitant decrease in C-terminal domain phosphorylation both for Ser2 and Ser5 was also observed (figure 5D), implicating an important role of PI3K in HMBA-induced HIV-1 expression. Furthermore, PI3K inhibitor also decreased the nuclear level of CDK9.
We also observed that the PKC-␣, PKC-␤1, and PKC-inhibitor Gö6976 inhibited HMBA-induced HIV-1 expression (figure 5B). To better identify the PKC isoform(s) critical for HMBA-induced HIV-1 expression, we treated cells with a PKC-␤1 inhibitor (3-(1-(3-imidazol-1-ylpropyl)-1H-indol-3-yl)-4-anilino-1H-pyrrole-2,5-dione) and with Gö6983, which inhibits PKC-␣, PKC-␤, PKC-␥, PKC-␦, and PKC-but not PKC-. We used submaximal concentration of these inhibitors to avoid significant cytotoxicity and observed 40%-50% inhibition of HMBA-induced HIV-1 expression.
Together, Gö6983 and the PKC-␤1 inhibitor did not inhibit HMBA-induced HIV-1 expression, suggesting a key role for PKC-in HMBA-induced HIV-1 expression ( figure 5C ). Because there is no specific inhibitor for PKC-, to test the role of PKC-in C-terminal domain phosphorylation by HMBA, we treated HeLa-CD4-LTR-CAT cells with either Gö6976 or Gö6983, as well as HMBA, to differentiate the role of PKCfrom that of other PKC isozymes. We observed that Gö6976 but not Gö6983 abrogated phosphorylation of both the Ser2 and Ser5 C-terminal domain residues, further implicating PKC-as a contributor to HMBA-induced HIV-1 expression (figure 5E). Treatment of the J89GFP cell line with both LY294002 and Gö6976, however, did not result in additive inhibition of Figure 3 . Hexamethylbisacetamide (HMBA) increases the nuclear levels of cyclin-dependent kinase 9 (CDK9) and hexamethylenebisacetamideinduced protein 1 (HEXIM1). HeLa-CD4-LTR-CAT cells were treated with 5 mmol/L of HMBA, and nuclear extract was prepared 0, 3, 6, and 9 h after treatment. Western blot analysis is representative of 3 experiments. CycT1, cyclin T1.
HMBA-induced HIV-1 expression (data not shown). These results suggest that both PKC-and PI3K play a key role in presentation of the catalytically active form of CDK9 to the HIV-1 promoter.
DISCUSSION
HMBA can activate HIV-1 expression in latently infected cell lines [41, 42] . Herein, we demonstrated that HMBA induces HIV-1 expression in latently infected resting CD4 ϩ T cells recovered from aviremic HIV-1-seropositive donors treated with ART. We studied the mechanisms by which HMBA disrupts latent infection. Our earlier study revealed that, in the absence of Tat, HMBA increases polymerase processivity at the LTR and remodels Nuc 1 chromatin without histone H3 or H4 acetylation or H3K4 methylation [11] . Herein, we further elucidated the mechanisms of HMBA-induced HIV-1 expression by demonstrating that HMBA induces phosphorylation of both Ser5 and Ser2 of the C-terminal domain of RNA Pol II, which is consistent with the role of the C-terminal domain in transcription initiation and elongation [45, 46] . Moreover, the ef- , and 9 h were subjected to chromatin immunoprecipitation (ChIP). A significant increase in CDK9 occupancy at the long terminal repeat (LTR) region was detected 9 h after HMBA exposure. D, HeLa-CD4-LTR-CAT cells were transfected with Sp1 siRNA or negative control siRNA. Forty-eight hours after transfection, Western blot and ChIP analysis confirmed decreased Sp1 levels and demonstrated decreased CDK9 occupancy at the LTR. E, ChIP assays of cells treated as described in D and with 5 mmol/L of HMBA showed that recruitment of CDK9 to the LTR is significantly decreased by RNA interference (RNAi) directed against Sp1. All results are representative of 3 independent experiments; the time to peak recruitment of CDK9 to HIV-1 LTR varied from 6-9 h after HMBA exposure in different experiments.
fect of HMBA on the RNA Pol II C-terminal domain and latent HIV-1 expression was CDK9 specific and abrogated by the CDK9 inhibitor flavopiridol. CDK9 normally phosphorylates Ser2, and Tat modifies the substrate specificity of CDK9, allowing the kinase to phosphorylate both Ser2 and Ser5 [47] . In this respect, HMBA acts in a manner similar to Tat by modifying the substrate specificity of CDK9.
HIV-1 has evolved Tat to redirect P-TEFb away from the regulatory protein HEXIM1 and recruit it to the viral promoter [25, 48] . How does HMBA accomplish this function in the absence of Tat? He et al. [33] have recently shown that, in a narrow window of time, HMBA increases the active pool of Brd4 -P-TEFb, although the mechanism of this effect is not yet understood. In addition to increasing the pool of P-TEFb that is not sequestered by HEXIM1, we found that HMBA increased the nuclear level of CDK9. We observed that CycT1/CDK9 binds to the HIV-1 promoter in an Sp1-dependent fashion in response to HMBA. RNA interference against Sp1 abrogated the occupancy of CDK9 at the HIV-1 LTR. Our results are consistent with those of Yedavalli et al. [39] , who found that Sp1 DNA binding sites were necessary for P-TEFb activity in the absence of Tat. Moreover, these results are consistent with the finding that Sp1 binding sites are necessary for HMBA-induced HIV-1 expression [41, 42] . Brd4 may also play a role in activation, but clarifying this point will require further study.
Active P-TEFb plays a key role in several cellular processes and is tightly regulated by a complex composed of HEXIM1 and 7SK snRNA [34, 35] . It was surprising to find that HMBA increased the nuclear level of HEXIM1 and its association with CycT1/ CDK9 at the peak of CDK9 recruitment to the HIV-1 promoter ( figure 3 ). These results, however, are consistent with the findings of Sung and Rice [32] , who also observed an increase in CDK9 activity despite an increase in the association of 7SK snRNA and HEXIM1 with CDK9. Both activation of CDK9 and its sequestration into 7SK/snRNA/ HEXIM1 have been linked to the phosphorylation of threonine at position 186 [43, 49] . Increased binding of CycT1/CDK9 to HEXIM1 at the peak of CDK9 activity in response to HMBA treatment may be linked to this phosphorylation. Sp1-bound CycT1/CDK9, the complex recruited to the LTR, was not associated with HEXIM1. This shows that HMBA increased nuclear levels of HEXIM1 but also increased nuclear levels of free, active CDK9. The level of 7SK snRNA is also limiting to complex formation in some settings, and insufficient levels of 7SK snRNA may allow for active, free CDK9 despite the presence of HEXIM1 [50] .
Posttranslational modification of CDK9 is critical to its stability, nuclear translocation, increased enzymatic activity, and sequestration into an inactive complex [43, 44, 49] . Our results suggest a role of PI3K and PKC-in these processes in response to HMBA. Treatment of cells with LY294002 and Gö6976 resulted in reduced Ser2 and Ser5 C-terminal domain phosphorylation and HIV-1 expression. HMBA induces PKC signaling, but this study is the first to directly demonstrate a role for PKC-in HIV-1 expression. In addition to the involvement of PKC-, our results indicate involvement of PI3K in the induction of LTR expression.
Induction of HIV-1 expression via PKC-is also unique in that, unlike prostratin (another PKC inducer), PKC-does not require Tat to induce LTR expression [32] . These findings suggest that PKC-and PI3K are novel targets for specific induction of the expression of latent HIV-1 in resting CD4 ϩ T cells.
